Table of Contents Author Guidelines Submit a Manuscript
Experimental Diabetes Research
Volume 2011 (2011), Article ID 898913, 8 pages
http://dx.doi.org/10.1155/2011/898913
Review Article

From Theory to Clinical Practice in the Use of GLP-1 Receptor Agonists and DPP-4 Inhibitors Therapy

Section of Endocrinology, Department of Clinical Pathophysiology, University of Florence, Viale Pieraccini 6, 50134 Florence, Italy

Received 23 February 2011; Accepted 14 April 2011

Academic Editor: Matteo Monami

Copyright © 2011 Ilaria Dicembrini et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. J. E. Shaw, R. A. Sicree, and P. Z. Zimmet, “Global estimates of the prevalence of diabetes for 2010 and 2030,” Diabetes Research and Clinical Practice, vol. 87, no. 1, pp. 4–14, 2010. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  2. R. Sturm, “Stemming the global obesity epidemic: what can we learn from data about social and economic trends?” Public Health, vol. 122, no. 8, pp. 739–746, 2008. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  3. K. K. Ray, S. R. K. Seshasai, S. Wijesuriya et al., “Effect of intensive control of glucose on cardiovascular outcomes and death in patients with diabetes mellitus: a meta-analysis of randomised controlled trials,” Lancet, vol. 373, no. 9677, pp. 1765–1772, 2009. View at Publisher · View at Google Scholar · View at Scopus
  4. E. Mannucci, M. Monami, C. Lamanna et al., “Prevention of cardiovascular disease through glycemic control in type 2 diabetes: a meta-analysis of randomized clinical trials,” Nutrition, Metabolism and Cardiovascular Diseases, vol. 19, no. 9, pp. 604–612, 2009. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  5. V. Preumont, M. P. Hermans, S. Brichard, and M. Buysschaert, “Six-month exenatide improves HOMA hyperbolic product in type 2 diabetic patients mostly by enhancing beta-cell function rather than insulin sensitivity,” Diabetes Metab, vol. 36, no. 4, pp. 293–8, 2010. View at Google Scholar
  6. A. Karasik, P. Aschner, H. Katzeff, M. J. Davies, and P. P. Stein, “Sitagliptin, a DPP-4 inhibitor for the treatment of patients with type 2 diabetes: a review of recent clinical trials,” Current Medical Research and Opinion, vol. 24, no. 2, pp. 489–496, 2008. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  7. B. Ahrén, G. Pacini, A. Tura, J. E. Foley, and A. Schweizer, “Improved meal-related insulin processing contributes to the enhancement of B-cell function by the DPP-4 inhibitor vildagliptin in patients with type 2 diabetes,” Hormone and Metabolic Research, vol. 39, no. 11, pp. 826–829, 2007. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  8. E. Mannucci, A. Ognibene, F. Cremasco et al., “Glucagon-like peptide (GLP)-1 and leptin concentrations in obese patients with type 2 diabetes mellitus,” Diabetic Medicine, vol. 17, no. 10, pp. 713–719, 2000. View at Publisher · View at Google Scholar · View at Scopus
  9. M. A. Nauck, I. Vardarli, C. F. Deacon, J. J. Holst, and J. J. Meier, “Secretion of glucagon-like peptide-1 (GLP-1) in type 2 diabetes: what is up, what is down?” Diabetologia, vol. 54, no. 1, pp. 10–8.
  10. C. M. Rotella, L. Pala, and E. Mannucci, “Glucagon-like peptide 1 (GLP-1) and metabolic diseases,” Journal of Endocrinological Investigation, vol. 28, no. 8, pp. 746–758, 2005. View at Google Scholar · View at Scopus
  11. E. Mannucci, A. Ognibene, F. Cremasco et al., “Effect of metformin on glucagon-like peptide 1 (GLP-1) and leptin levels in obese nondiabetic subjects,” Diabetes Care, vol. 24, no. 3, pp. 489–494, 2001. View at Google Scholar · View at Scopus
  12. E. Mannucci, F. Tesi, G. Bardini et al., “Effects of metformin on glucagon-like peptide-1 levels in obese patients with and without type 2 diabetes,” Diabetes, nutrition & metabolism, vol. 17, no. 6, pp. 336–342, 2004. View at Google Scholar · View at Scopus
  13. E. Mannucci, L. Pala, M. Monami et al., “Glucagon-like peptide-1 response to meals and post-prandial hyperglycemia in type 2 diabetic patients,” Journal of Endocrinological Investigation, vol. 33, no. 3, pp. 147–150, 2010. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  14. L. Pala, S. Ciani, I. Dicembrini et al., “Relationship between GLP-1 levels and dipeptidyl peptidase-4 activity in different glucose tolerance conditions,” Diabetic Medicine, vol. 27, no. 6, pp. 691–695, 2010. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  15. L. Pala, E. Mannucci, A. Pezzatini et al., “Dipeptidyl peptidase-IV expression and activity in human glomerular endothelial cells,” Biochemical and Biophysical Research Communications, vol. 310, no. 1, pp. 28–31, 2003. View at Publisher · View at Google Scholar · View at Scopus
  16. E. Mannucci, L. Pala, S. Ciani et al., “Hyperglycaemia increases dipeptidyl peptidase IV activity in diabetes mellitus,” Diabetologia, vol. 48, no. 6, pp. 1168–1172, 2005. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  17. L. Pala, A. Pezzatini, I. Dicembrini et al., “Different modulation of dipeptidyl peptidase-4 activity between microvascular and macrovascular human endothelial cells,” Acta Diabetol. In press.
  18. M. A. Nauck, “Incretin-based therapies for type 2 diabetes mellitus: properties, functions, and clinical implications,” American Journal of Medicine, vol. 124, no. 1, pp. s3–s18, 2011. View at Google Scholar
  19. A. Varanasi, A. Chaudhuri, S. Dhindsa et al., “Durability of effects of exenatide treatment on glycemic control, body weight, systolic blood pressure, Crp and triglyceride concentrations,” Endocrine Practice, vol. 17, no. 2, pp. 192–200, 2010. View at Google Scholar
  20. M. J. Davies, R. Kela, and K. Khunti, “Overview of the preclinical and clinical data and its role in the treatment of type 2 diabetes,” Diabetes, Obesity and Metabolism, vol. 13, no. 3, pp. 207–20, 2011. View at Google Scholar
  21. B. Ahrén, “Are sulfonylureas less desirable than DPP-4 inhibitors as add-on to metformin in the treatment of type 2 diabetes?” Current diabetes reports . In press.
  22. J. H. Best, B. J. Hoogwerf, W. H. Herman et al., “Risk of cardiovascular disease events in patients with type 2 diabetes prescribed the glucagon-like peptide 1 (GLP-1) receptor agonist exenatide twice daily or other glucose-lowering therapies: a retrospective analysis of the lifeLink database,” Diabetes Care, vol. 34, no. 1, pp. 90–5, 2011. View at Google Scholar
  23. M. Monami, I. Iacomelli, N. Marchionni, and E. Mannucci, “Dipeptydil peptidase-4 inhibitors in type 2 diabetes: a meta-analysis of randomized clinical trials,” Nutrition, Metabolism and Cardiovascular Diseases, vol. 20, no. 4, pp. 224–235, 2010. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  24. P. A. Read, F. Z. Khan, P. M. Heck, S. P. Hoole, and D. P. Dutka, “DPP-4 inhibition by sitagliptin improves the myocardial response to dobutamine stress and mitigates stunning in a pilot study of patients with coronary artery disease,” Circulation: Cardiovascular Imaging, vol. 3, no. 2, pp. 195–201, 2010. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  25. H. D. Theiss, C. Brenner, M. G. Engelmann et al., “Safety and efficacy of SITAgliptin plus GRanulocyte-colony-stimulating factor in patients suffering from acute myocardial infarction (SITAGRAMI-Trial)–Rationale, design and first interim analysis,” International Journal of Cardiology, 2010. View at Publisher · View at Google Scholar · View at PubMed
  26. J. P. Courrèges, T. Vilsbøll, M. Zdravkovic et al., “Beneficial effects of once-daily liraglutide, a human glucagon-like peptide-1 analogue, on cardiovascular risk biomarkers in patients with type 2 diabetes,” Diabetic Medicine, vol. 25, no. 9, pp. 1129–1131, 2008. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  27. P. Viswanathan, A. Chaudhuri, R. Bhatia, F. Al-Atrash, P. Mohanty, and P. Dandona, “Exenatide therapy in obese patients with type 2 diabetes mellitus treated with insulin,” Endocrine Practice, vol. 13, no. 5, pp. 444–450, 2007. View at Google Scholar · View at Scopus
  28. M. Arakawa, T. Mita, K. Azuma et al., “Inhibition of monocyte adhesion to endothelial cells and attenuation of atherosclerotic lesion by a glucagon-like peptide-1 receptor agonist, exendin-4,” Diabetes, vol. 59, no. 4, pp. 1030–1037, 2010. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  29. Y. Ye, K. T. Keyes, C. Zhang, J. R. Perez-Polo, YU. Lin, and Y. Birnbaum, “The myocardial infarct size-limiting effect of sitagliptin is PKA-dependent, whereas the protective effect of pioglitazone is partially dependent on PKA,” American Journal of Physiology, vol. 298, no. 5, pp. H1454–1465, 2010. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  30. D. C. Klonoff, J. B. Buse, L. L. Nielsen et al., “Exenatide effects on diabetes, obesity, cardiovascular risk factors and hepatic biomarkers in patients with type 2 diabetes treated for at least 3 years,” Current Medical Research and Opinion, vol. 24, no. 1, pp. 275–286, 2008. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  31. J. Jendle, M. A. Nauck, D. R. Matthews et al., “LEAD-2 and LEAD-3 study groups. weight loss with liraglutide, a once-daily human glucagon-like peptide-1 analogue for type 2 diabetes treatment as monotherapy or added to metformin, is primarily as a result of a reduction in fat tissue,” Diabetes, Obesity and Metabolism, vol. 11, no. 12, pp. 1163–72, 2009. View at Google Scholar
  32. S. R. Drab, “Incretin-based therapies for type 2 diabetes mellitus: current status and future prospects,” Pharmacotherapy, vol. 30, no. 6, pp. 609–624, 2010. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  33. L. Blonde and D. Russell-Jones, “The safety and efficacy of liraglutide with or without oral antidiabetic drug therapy in type 2 diabetes: an overview of the LEAD 1-5 studies,” Diabetes, Obesity and Metabolism, vol. 11, no. 3, pp. 26–34, 2009. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  34. W. Wang, J. R. Walker, X. Wang et al., “Identification of small-molecule inducers of pancreatic β-cell expansion,” Proceedings of the National Academy of Sciences of the United States of America, vol. 106, no. 5, pp. 1427–1432, 2009. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  35. B. L. Wajchenberg, “Beta-cell failure in diabetes and preservation by clinical treatment,” Endocrine Reviews, vol. 28, no. 2, pp. 187–218, 2007. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  36. D. M. Kendall, M. C. Riddle, J. Rosenstock et al., “Effects of exenatide (exendin-4) on glycemic control over 30 weeks in patients with type 2 diabetes treated with metformin and a sulfonylurea,” Diabetes Care, vol. 28, no. 5, pp. 1083–1091, 2005. View at Publisher · View at Google Scholar · View at Scopus
  37. J. B. Buse, R. R. Henry, J. Han, D. D. Kim, M. S. Fineman, and A. D. Baron, “For the e xenatide-113 clinical study group. effects of exenatide (exendin-4) on glycemic control over 30 weeks in sulfonylurea-treated patients with type 2 diabetes,” Diabetes Care, vol. 27, pp. 2628–3, 2004. View at Google Scholar
  38. R. A. DeFronzo, R. E. Ratner, J. Han, D. D. Kim, M. S. Fineman, and A. D. Baron, “Effects of exenatide (exendin-4) on glycemic control and weight over 30 weeks in metformin-treated patients with type 2,” Diabetes Care, vol. 28, no. 5, pp. 1092–1100, 2005. View at Publisher · View at Google Scholar · View at Scopus
  39. L. Blonde, E. J. Klein, J. Han et al., “Interim analysis of the effects of exenatide treatment on A1C, weight and cardiovascular risk factors over 82 weeks in 314 overweight patients with type 2 diabetes,” Diabetes, Obesity and Metabolism, vol. 8, no. 4, pp. 436–447, 2006. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  40. M. C. Bunck, M. Diamant, A. Cornér et al., “One-year treatment with exenatide improves beta-cell function, compared with insulin glargine, in metformin-treated type 2 diabetic patients: a randomized, controlled trial,” Diabetes Care, vol. 32, no. 5, pp. 762–8, 2009. View at Google Scholar
  41. R. J. Heine, L. F. Van Gaal, D. Johns, M. J. Mihm, M. H. Widel, and R. G. Brodows, “GWAA study group. exenatide versus insulin glargine in patients with suboptimally controlled type 2 diabetes: a randomized trial,” Annals of Internal Medicine, vol. 143, no. 8, pp. 559–69, 2005. View at Google Scholar
  42. A. H. Barnett, J. Burger, D. Johns et al., “Tolerability and efficacy of exenatide and titrated insulin glargine in adult patients with type 2 diabetes previously uncontrolled with metformin or a sulfonylurea: a multinational, randomized, open-label, two-period, crossover noninferiority trial,” Clinical Therapeutics, vol. 29, no. 11, pp. 2333–2348, 2007. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  43. M. A. Nauck, S. Duran, D. Kim et al., “A comparison of twice-daily exenatide and biphasic insulin aspart in patients with type 2 diabetes who were suboptimally controlled with sulfonylurea and metformin: a non-inferiority study,” Diabetologia, vol. 50, no. 2, pp. 259–267, 2007. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  44. W. K. Fakhoury, C. LeReun, and D. Wright, “A meta-analysis of placebo-controlled clinical trials assessing the efficacy and safety of incretin-based medications in patients with type 2 diabetes,” Pharmacology, vol. 86, no. 1, pp. 44–57, 2010. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  45. G. Derosa, P. Maffioli, S. A. Salvadeo et al., “Exenatide versus glibenclamide in patients with diabetes,” Diabetes Technology & Therapeutics, vol. 12, no. 3, pp. 233–40, 2010. View at Google Scholar
  46. M. Marre, J. Shaw, M. Brändle et al., “LEAD-1 SU study group. liraglutide, a once-daily human GLP-1 analogue, added to a sulphonylurea over 26 weeks produces greater improvements in glycaemic and weight control compared with adding rosiglitazone or placebo in subjects with type 2 diabetes (LEAD-1 SU),” Diabetic Medicine, vol. 26, no. 3, pp. 268–78, 2009. View at Google Scholar
  47. M. Nauck, A. Frid, K. Hermansen et al., “LEAD-2 study group. efficacy and safety comparison of liraglutide, glimepiride, and placebo, all in combination with metformin, in type 2 diabetes: the LEAD (liraglutide effect and action in diabetes)-2 study,” Diabetes Care, vol. 32, no. 1, pp. 84–90, 2009. View at Google Scholar
  48. D. Russell-Jones, A. Vaag, and O. Schmitz, “Liraglutide vs insulin glargine and placebo in combination with metformin and sulfonylurea therapy in type 2 diabetes mellitus (LEAD-5 met+SU): a randomized controlled trial liraglutide effect and action in diabetes 5 (LEAD-5) met+SU study group,” Diabetologia, vol. 52, no. 10, pp. 2046–55, 2009. View at Google Scholar
  49. J. B. Buse, J. Rosenstock, G. Sesti et al., “LEAD-6 study group.liraglutide once a day versus exenatide twice a day for type 2 diabetes: a 26-week randomised, parallel-group, multinational, open-label trial (LEAD-6),” Lancet, vol. 374, no. 9683, pp. 39–47, 2009. View at Publisher · View at Google Scholar · View at Scopus
  50. C. A. Sheffield, M. P. Kane, R. S. Busch et al., “Safety and efficacy of exenatide in combination with insulin in patients with type 2 diabetes mellitus,” Endocrine Practice, vol. 14, no. 3, pp. 285–292, 2008. View at Google Scholar · View at Scopus
  51. A. J. Scheen, “Pharmacokinetics of dipeptidylpeptidase-4 inhibitors,” Diabetes, Obesity and Metabolism:, vol. 12, no. 8, pp. 648–58, 2010. View at Google Scholar
  52. A. J. Scheen, “Dipeptidylpeptidase-4 inhibitors (gliptins): focus on drug-drug interactions,” Clin Pharmacokinet, vol. 49, no. 9, pp. 573–88, 2010. View at Google Scholar
  53. C. F. Deacon, “Dipeptidyl peptidase-4 inhibitors in the treatment of type 2 diabetes: a comparative review,” Diabetes, Obesity and Metabolism, vol. 13, no. 1, pp. 7–18, 2011. View at Google Scholar
  54. J. E. Foley and S. Sreenan, “Efficacy and safety comparison between the DPP-4 inhibitor vildagliptin and the sulfonylurea gliclazide after two years of monotherapy in drug-naïve patients with type 2 diabetes,” Horm Metab Res, vol. 41, no. 12, pp. 905–9, 2009. View at Google Scholar
  55. D. A. D'Alessio, A. M. Denney, L. M. Hermiller et al., “Treatment with the dipeptidyl peptidase-4 inhibitor vildagliptin improves fasting islet-cell function in subjects with type 2 diabetes,” Journal of Clinical Endocrinology and Metabolism, vol. 94, no. 1, pp. 81–88, 2009. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  56. J. E. Foley and J. Jordan, “Weight neutrality with the DPP-4 inhibitor, vildagliptin: mechanistic basis and clinical experience,” Vascular Health and Risk Management, vol. 6, pp. 541–8, 2010. View at Google Scholar
  57. M. Ligueros-Saylan, J. E. Foley, A. Schweizer, A. Couturier, and W. Kothny, “An assessment of adverse effects of vildagliptin versus comparators on the liver, the pancreas, the immune system, the skin and in patients with impaired renal function from a large pooled database of phase II and III clinical trials,” Diabetes, Obesity and Metabolism, vol. 12, no. 6, pp. 495–509, 2010. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  58. M. Haidinger, J. Werzowa, H. C. Voigt et al., “A randomized, placebo-controlled, double-blind, prospective trial to evaluate the effect of vildagliptin in new-onset diabetes mellitus after kidney transplantation,” Trials, vol. 11, no. 1, p. 91, 2010. View at Google Scholar
  59. M. A. Banerji, D. Purkayastha, and B. H. Francis, “Safety and tolerability of vildagliptin vs. thiazolidinedione as add-on to metformin in type 2 diabetic patients with and without mild renal impairment: a retrospective analysis of the GALIANT study,” Diabetes Research and Clinical Practice, vol. 90, no. 2, pp. 182–90, 2010. View at Google Scholar
  60. M. Hanefeld, G. A. Herman, M. Wu, C. Mickel, M. Sanchez, and P. P. Stein, “Sitagliptin study 014 investigators.once-daily sitagliptin, a dipeptidyl peptidase-4 inhibitor, for the treatment of patients with type 2 diabetes,” Current Medical Research and Opinion, vol. 23, no. 6, pp. 1329–39, 2007. View at Google Scholar
  61. C. J. Bailey, B. D. Green, and P. R. Flatt, “Fixed-dose combination therapy for type 2 diabetes: sitagliptin plus pioglitazone,” Expert Opinion on Investigational Drugs, vol. 19, no. 8, pp. 1017–25, 2010. View at Google Scholar
  62. S. S. Engel, D. E. Williams-Herman, G. T. Golm et al., “Sitagliptin: review of preclinical and clinical data regarding incidence of pancreatitis,” International Journal of Clinical Practice, vol. 64, no. 7, pp. 984–990, 2010. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  63. A. J. Scheen, “Saxagliptin (Onglyza): new inhibitor of the dipeptidylpeptidase-4 for the oral treatment of type 2 diabetes,” Revue Medicale De Liege, vol. 65, no. 9, pp. 527–32, 2010. View at Google Scholar
  64. J. Rosenstock, C. Aguilar-Salinas, E. Klein et al., “Effect of saxagliptin monotherapy in treatment-naïve patients with type 2 diabetes,” Current Medical Research and Opinion, vol. 25, no. 10, pp. 2401–2411, 2009. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  65. M. Jadzinsky, A. Pfützner, E. Paz-Pacheco et al., “Saxagliptin given in combination with metformin as initial therapy improves glycaemic control in patients with type 2 diabetes compared with either monotherapy: a randomized controlled trial,” Diabetes, Obesity and Metabolism, vol. 11, no. 6, pp. 611–622, 2009. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  66. A. R. Chacra, G. H. Tan, A. Apanovitch, S. Ravichandran, J. List, and R. Chen, “Saxagliptin added to a submaximal dose of sulphonylurea improves glycaemic control compared with uptitration of sulphonylurea in patients with type 2 diabetes: a randomised controlled trial,” International Journal of Clinical Practice, vol. 63, no. 9, pp. 1395–1406, 2009. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  67. P. Hollander, J. Li, E. Allen, and R. Chen, “For the CV181-013 investigators.saxagliptin added to a thiazolidinedione improves glycemic control in patients with type 2 diabetes and inadequate control on thiazolidinedione alone,” Journal of Clinical Endocrinology and Metabolism, vol. 94, no. 12, pp. 4810–4819, 2009. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  68. R. A. DeFronzo, M. Hissa, A. J. Garber et al., “The efficacy and safety of saxagliptin when added to metformin therapy in patients with inadequately controlled type 2 diabetes with metformin alone,” Diabetes Care, vol. 32, no. 9, pp. 1649–1655, 2009. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  69. M. Nowicki, I. Rychlik, H. Haller, M. L. Warren, L. Suchower, and I. Gause-Nilsson, “Saxagliptin improves glycaemic control and is well tolerated in patients with type 2 diabetes mellitus and renal impairment,” Diabetes, Obesity and Metabolism, vol. 13, no. 6, pp. 523–532, 2011. View at Google Scholar
  70. A. J. Scheen, G. Charpentier, C. J. Ostgren, A. Hellqvist, and I. Gause-Nilsson, “Efficacy and safety of saxagliptin in combination with metformin compared with sitagliptin in combination with metformin in adult patients with type 2 diabetes mellitus,” Diabetes Metab Res Rev, vol. 26, no. 7, pp. 504–9, 2010. View at Google Scholar
  71. R. M. Bergenstal, C. Wysham, L. Macconell et al., “DURATION-2 study group. efficacy and safety of exenatide once weekly versus sitagliptin or pioglitazone as an adjunct to metformin for treatment of type 2 diabetes (DURATION-2): a randomised trial,” Lancet, vol. 376, no. 9739, pp. 431–439, 2010. View at Google Scholar
  72. E. Mannucci and C. M. Rotella, “Future perspectives on glucagon-like peptide-1, diabetes and cardiovascular risk,” Nutrition, Metabolism and Cardiovascular Diseases, vol. 18, no. 9, pp. 639–645, 2008. View at Publisher · View at Google Scholar · View at PubMed
  73. A Astrup, S Rössner, L Van Gaal et al., “NN8022-1807 study group. effects of liraglutide in the treatment of obesity: a randomised, double-blind, placebo-controlled study.,” Lancet, vol. 374, no. 9701, pp. 1606–16, 2009. View at Google Scholar
  74. G. Bock, C. Dalla Man, F. Micheletto et al., “The effect of DPP-4 inhibition with sitagliptin on incretin secretion and on fasting and postprandial glucose turnover in subjects with impaired fasting glucose,” Clinical Endocrinology (Oxf), vol. 73, no. 2, pp. 189–196, 2010. View at Google Scholar
  75. S. Madsbad, U. Kielgast, M. Asmar, C. Deacon, S. S. Torekov, and J. J. Holst, “An overview of once-weekly GLP-1 receptor agonists- available efficacy and safety data and perspectives for the future,” Diabetes, Obesity and Metabolism, vol. 13, no. 5, pp. 394–407, 2011. View at Google Scholar